{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:02:47Z","timestamp":1793664167021,"version":"4.5.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Impella 5.0 and 5.5 are promising low-invasive left ventricle (LV) temporary mechanical circulatory supports (tMCS) for cardiogenic shock due to LV mechanical unloading and are paired with powerful hemodynamic support. This study aimed to analyze data and destinies of patients supported with Impella 5.0\/5.5 at a national referral center for cardiogenic shock and to assess the parameters associated with myocardial recovery and successful weaning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single-center observational study was conducted on all patients treated with Impella 5.0 or 5.5 from March 2018 to July 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 59 patients underwent Impella 5.0\/5.5 implantation due to profound cardiogenic shock, with acute myocardial infarction being the most frequent cause of shock (42 patients, 71%). The median duration of Impella support was 13 days (maximum duration of 52 days). Axillary cannulation was feasible in almost all patients, and 36% were mobilized during support. A total of 44 patients (75%) survived to the next therapy\/recovery: 21 patients experienced recovery and 15 and 8 were bridged to long-term LVAD and heart transplantation, respectively. The global survival rate was 66%. The predictors of native heart recovery at multivariate analysis were the number of days on tMCS before upgrade to Impella 5.0\/5.5 [hazard ratio (HR) 0.68 (0.51\u20139) <jats:italic>p<\/jats:italic>\u2009=\u20090.0068] and improvement of LVEF within the first 7\u201310 days of support [HR 4.72 (1.34\u201316.7), <jats:italic>p<\/jats:italic>\u2009=\u20090.016].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Transcatheter systems such as Impella 5.0\/5.5 revolutionized the field of tMCS. Myocardial recovery is the primary clinical target. Its prognostication and promotion are key to ensure the most proficuous course for each patient from cardiogenic shock to long-term event-free survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1379199","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:46:12Z","timestamp":1719927972000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Prolonged Impella 5.0\/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center"],"prefix":"10.3389","volume":"11","author":[{"given":"Marina","family":"Pieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ortalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Altizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Fominskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Lapenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ajello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mara","family":"Scandroglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jacc.2019.07.077","article-title":"Cardiogenic shock classification to predict mortality in the cardiac intensive care unit","volume":"74","author":"Jentzer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijcard.2020.09.044","article-title":"Short term outcomes of Impella in cardiogenic shock: a review and meta-analysis of observational studies","volume":"324","author":"Iannaccone","year":"2021","journal-title":"Int J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/IMI.0000000000000535","article-title":"Outcomes of Impella 5.0 in cardiogenic shock: a systematic review and meta-analysis","volume":"13","author":"Batsides","year":"2018","journal-title":"Innovations (Phila)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13019-020-01251-7","article-title":"The role of the axillary Impella 5.0 device on patients with acute cardiogenic shock","volume":"15","author":"Tarabichi","year":"2020","journal-title":"J Cardiothorac Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/ccd.29593","article-title":"Mechanical circulatory support in acute myocardial infarction and cardiogenic shock: challenges and importance of randomized control trials","volume":"98","author":"Basir","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.amjcard.2019.10.040","article-title":"Trends, outcomes, and predictors of revascularization in cardiogenic shock","volume":"125","author":"Khan","year":"2020","journal-title":"Am J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2020.12.054","article-title":"Managing patients with short-term mechanical circulatory support: JACC Review Topic of the Week","volume":"77","author":"Balthazar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/jocs.13978","article-title":"Surgical transaxillary placement of the Impella 5.0 ventricular assist device","volume":"34","author":"Bertoglio","year":"2019","journal-title":"J Card Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/MAT.0000000000000877","article-title":"Clinical outcomes of Impella microaxial devices used to salvage cardiogenic shock as a bridge to durable circulatory support or cardiac transplantation","volume":"65","author":"Cheng","year":"2019","journal-title":"ASAIO J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/ejcts\/ezz118","article-title":"Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes","volume":"56","author":"Bernhardt","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.amjcard.2016.02.038","article-title":"Effectiveness and safety of the Impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device","volume":"117","author":"Lima","year":"2016","journal-title":"Am J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ejcts\/ezz179","article-title":"Mechanical circulatory support with the Impella 5.0 and the Impella left direct pumps for postcardiotomy cardiogenic shock at La Piti\u00e9-Salp\u00eatri\u00e8re hospital","volume":"57","author":"David","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17434440.2022.2015323","article-title":"Device profile of the Impella 5.0 and 5.5 system for mechanical circulatory support for patients with cardiogenic shock: overview of its safety and efficacy","volume":"19","author":"Pahuja","year":"2022","journal-title":"Expert Rev Med Devices"},{"key":"B16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/15569845211013329","article-title":"Early outcomes of the first 200 US patients treated with Impella 5.5: a novel temporary left ventricular assist device","volume":"16","author":"Ramzy","year":"2021","journal-title":"Innovations (Phila)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.healun.2021.04.001","article-title":"First in man evaluation of a novel circulatory support device: early experience with the Impella 5.5 after CE mark approval in Germany","volume":"40","author":"Bernhardt","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1002\/ehf2.13512","article-title":"A case series analysis on the clinical experience of Impella 5.5\u00ae at a large tertiary care centre","volume":"8","author":"Kennel","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/2048872619865891","article-title":"Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP\/5.0 versus ECMO","volume":"9","author":"Karami","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/CIRCRESAHA.121.318160","article-title":"Reverse remodeling with left ventricular assist devices","volume":"128","author":"Burkhoff","year":"2021","journal-title":"Circ Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11936-013-0287-9","article-title":"Treatment strategies for myocardial recovery in heart failure","volume":"16","author":"Lenneman","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1053\/j.jvca.2013.10.004","article-title":"Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step?","volume":"28","author":"Pappalardo","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/aor.12168","article-title":"Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices","volume":"38","author":"Pieri","year":"2014","journal-title":"Artif Organs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.healun.2020.03.010","article-title":"Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium","volume":"39","author":"Kormos","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1018203","DOI":"10.3389\/fcvm.2023.1018203","article-title":"Single center experience and early outcomes of Impella 5.5","volume":"10","author":"Funamoto","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"856870","DOI":"10.3389\/fcvm.2022.856870","article-title":"Ventricular unloading using the Impella\u2122 device in cardiogenic shock","volume":"9","author":"Attinger-Toller","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1171956","DOI":"10.3389\/fcvm.2023.1171956","article-title":"Clinical outcomes and predictors of success with Impella weaning in cardiogenic shock: a single-center experience","volume":"10","author":"Matassini","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"I24","DOI":"10.1093\/eurheartjsupp\/suad130","article-title":"Monitoring MCS patients on the intensive care unit: integrating haemodynamic assessment, laboratory data, and imaging techniques for timely detection of deterioration and recovery","volume":"25","author":"Vandenbriele","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"B29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1067\/mtc.2000.107833","article-title":"Mechanical support with microaxial blood pumps for postcardiotomy left ventricular failure: can outcome be predicted?","volume":"120","author":"Meyns","year":"2000","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003157","article-title":"Myocardial recovery in patients receiving contemporary left ventricular assist devices: results from the interagency registry for mechanically assisted circulatory support (INTERMACS)","volume":"9","author":"Topkara","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: special focus on framing the impact of adverse events","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1379199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:46:15Z","timestamp":1719927975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1379199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2024.1379199"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1379199","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"article-number":"1379199"}}